150 filings
Page 5 of 8
6-K
j1ccd8s8eh2 n8
29 Jan 19
ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
8:47am
6-K
d3jd491ry6ezw
7 Jan 19
ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
7:05am
6-K
ggffq3jbr 0jkzc4bv5
13 Dec 18
ProQR Announces Strategic Changes to the Management Team and Key New Hires
7:30am
6-K
eormkwjssc6s 0l8t
10 Dec 18
ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10
4:18pm
6-K
ve6r59uxegm sdxy2w
4 Dec 18
ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
8:38am
6-K
81icnu2bnmk9
7 Nov 18
PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements
4:40pm
6-K
vof2ou5
29 Oct 18
Current report (foreign)
4:30pm
6-K
1nn1785
7 Sep 18
ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares
12:00am
6-K
1raz2
5 Sep 18
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
12:00am
6-K
ulqmmz3nl4ft
5 Sep 18
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
12:00am
6-K
y8c01ju9bsu1xu65
8 Aug 18
PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements
4:37pm
6-K
aibehfx0c40y
29 Jun 18
ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa
8:10am
6-K
qoni81uyej2e6iosm
12 Jun 18
The funding will be used for the clinical development of QR-313
12:00am
6-K
7bu2l
16 May 18
Current report (foreign)
4:30pm
6-K
5nn3b2 y9
10 May 18
PROQR THERAPEUTICS N.V. Unaudited Condensed Consolidated Statement of Financial Position
6:55am
6-K
gyub7bc1z4j1 8gbw
23 Apr 18
ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO
12:00am
6-K
yb0mz7uj
11 Apr 18
ProQR Announces Annual Meeting of Shareholders
12:00am
6-K
ly7ov3g8nkvwt2q84e5
28 Feb 18
Index to Unaudited Condensed Consolidated Financial Statements
12:00am
6-K
qn6e l376t0lo
20 Feb 18
Current report (foreign)
12:00am
6-K
im7zn sa93e89eexzy02
12 Feb 18
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidateQR-421a for Usher syndrome type 2A
12:00am